Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 24615368)

1.

Do prior authorization policies discourage first-line antipsychotic use in patients newly discharged from a hospitalization for schizophrenia in Saskatchewan?

Blackburn DF, Tran D, Crawley A, Lynds S, Champagne A, Bresee L, Remillard AJ.

J Popul Ther Clin Pharmacol. 2014;21(1):e31-7. Epub 2014 Feb 10.

2.

The expert consensus guideline series. Treatment of behavioral emergencies 2005.

Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP; Expert Consensus Panel for Behavioral Emergencies 2005.

J Psychiatr Pract. 2005 Nov;11 Suppl 1:5-108; quiz 110-2.

PMID:
16319571
3.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
4.

Risperidone versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626. doi: 10.1002/14651858.CD006626.pub2. Review.

5.

Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001-2009).

Xiang YT, Kreyenbuhl J, Dickerson FB, Ungvari GS, Wang CY, Si TM, Lee EH, He YL, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N.

Aust N Z J Psychiatry. 2012 Dec;46(12):1159-64. doi: 10.1177/0004867412453625. Epub 2012 Jul 11.

PMID:
22790175
6.

Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.

Lin CY, Tsai GE, Wang HS, Wu YH, Chiou CC, Wu VY, Lane HY.

J Clin Psychiatry. 2014 Sep;75(9):e924-31. doi: 10.4088/JCP.13m08843.

PMID:
25295435
7.

Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.

Karagianis J, Williams R, Davis L, Procyshyn R, Monga N, Hanley J, Chandrasena R, Thakur A, Dickson R.

Curr Med Res Opin. 2009 Sep;25(9):2121-32. doi: 10.1185/03007990903102966.

PMID:
19601707
8.

Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.

Van Dorn RA, Andel R, Boaz TL, Desmarais SL, Chandler K, Becker MA, Howe A.

J Clin Psychiatry. 2011 Apr;72(4):502-8. doi: 10.4088/JCP.10m06618.

PMID:
21527125
9.

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S.

Schizophr Res. 2010 Nov;123(2-3):225-33. doi: 10.1016/j.schres.2010.07.012. Epub 2010 Aug 7. Review.

10.

Olanzapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review.

11.

Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.

Law MR, Ross-Degnan D, Soumerai SB.

Psychiatr Serv. 2008 May;59(5):540-6. doi: 10.1176/appi.ps.59.5.540.

PMID:
18451014
13.

The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

Naber D, Lambert M.

CNS Drugs. 2009 Aug;23(8):649-59. doi: 10.2165/00023210-200923080-00002.

PMID:
19594194
14.

National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom.

Prah P, Petersen I, Nazareth I, Walters K, Osborn D.

Pharmacoepidemiol Drug Saf. 2012 Feb;21(2):161-9. doi: 10.1002/pds.2213. Epub 2011 Aug 19.

PMID:
21858898
15.

Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.

Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR.

J Am Pharm Assoc (2003). 2007 May-Jun;47(3):373-8.

PMID:
17510032
16.

Effectiveness of second-generation antipsychotics with acute-phase schizophrenia.

Hatta K, Sato K, Hamakawa H, Takebayashi H, Kimura N, Ochi S, Sudo Y, Asukai N, Nakamura H, Usui C, Kawabata T, Hirata T, Sawa Y.

Schizophr Res. 2009 Aug;113(1):49-55. doi: 10.1016/j.schres.2009.05.030. Epub 2009 Jun 24.

PMID:
19553086
17.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
18.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
19.

Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary.

Bitter I, Katona L, Zámbori J, Takács P, Fehér L, Diels J, Bacskai M, Lang Z, Gyáni G, Czobor P.

Eur Neuropsychopharmacol. 2013 Nov;23(11):1383-90. doi: 10.1016/j.euroneuro.2013.02.003. Epub 2013 Mar 7.

PMID:
23477752
20.

Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain.

Sanfélix-Gimeno G, Cervera-Casino P, Peiró S, López-Valcarcel BG, Blázquez A, Barbera T.

Drug Saf. 2009;32(11):1075-87. doi: 10.2165/11316520-000000000-00000.

PMID:
19810779
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk